
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lamin A CRISPR Activation Plasmid (h) | sc-400039-ACT | 20 µg | $397.00 | |||
Lamin A CRISPR Activation Plasmid (h2) | sc-400039-ACT-2 | 20 µg | $397.00 |
LMNA encodes lamin A, a type V intermediate filament protein that polymerizes with lamin C to form the nuclear lamina and support nuclear envelope integrity. Lamin A regulates chromatin organization, genome stability, and mechanotransduction by coupling the nucleoskeleton to the cytoskeleton through the LINC complex, influencing transcriptional programs and DNA damage responses. It is integrated into processes including nuclear pore function, mitotic nuclear reassembly, and lamina-associated domain (LAD) positioning, which collectively shape cell fate and stress signaling. Dysregulation of LMNA is linked to laminopathies affecting muscle, adipose, and cardiac tissues, and it is frequently studied for its roles in premature aging phenotypes, nuclear morphology defects, and altered gene expression.
Lamin A CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous LMNA expression without altering the underlying DNA sequence.
Lamin A CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the LMNA locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the LMNA transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Lamin A expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native LMNA locus and enabling the study of Lamin A-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Lamin A pathway restoration in tumor cells with silenced or reduced LMNA expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.